ENvue Medical, Inc. 8-KCurrent Reports (8-K / ad hoc)

Business

Item 1.01 Entry into a Material Definitive Agreement Secured Promissory Note and Security Agreement On October 8, 2026, ENvue Medical, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt (the “Lender”), pursuant to which the Lender agreed to provide the Company with financing in an aggregate principal amount of up to $1,000,000, to be funded in tranches agreed to between the Company and the Lender. On October 8, 2026, the Lender funded an initial tranche in the principal amount of $250,000. Amounts outstanding under the Note and Security Agreement accrue interest at a rate of 10% per annum. Following the occurrence and during the continuance of an Event of Default, the interest rate increases to the lesser of 18% per annum or the highest rate permitted by applicable law. The outstanding principal amount, together with accrued interest, is due on December 31, 2026, provided that the Lender has the right to extend the maturity date in three-month increments through December 31, 2028. The Company’s obligations under the Note and Security Agreement are secured by a continuing security interest in substantially all of the assets of the Company, including its accounts, inventory, certain deposits, intellectual property and equity ownership of its subsidiaries, together with certain related proceeds and rights. The Note and Security Agreement authorizes the Lender to file financing statements and make other governmental filings to perfect and record its security interest in the collateral. The foregoing description of the Note and Security Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Note and Security Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Series X Amendment Agreement On October 8, 2026, the Company entered into an Amendment Agreement (the “Amendment Agreement”) with holders of at least 70% of the outstanding shares of the Company’s Series X Non-Voting Convertible Preferred Stock (the “Series X Preferred Stock”), amending certain terms of the Series X Preferred Stock as originally set forth in the Certificate of Designations of Preferences, Rights and Limitations of the Series X Preferred Stock (the “Certificate of Desi